nipocalimab

Maternal Nipocalimab Therapy for Severe HDFN: Evidence of Neonatal Safety and Immunological Recovery

The UNITY study demonstrates that antenatal nipocalimab treatment for severe HDFN effectively reduces fetal risk while resulting in only transient neonatal hypogammaglobulinemia. Findings confirm low fetal drug exposure and robust long-term

FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results